Mon Nov 17 22:00:00 UTC 2025: Here’s a summary of the text, followed by a rewrite as a news article:
Summary:
Novo Nordisk is lowering the direct-to-consumer prices of its weight loss drug Wegovy and diabetes drug Ozempic for cash-paying customers. The move follows agreements between the Trump administration and Novo Nordisk, along with competitor Eli Lilly, to increase access to these popular GLP-1 drugs. Novo Nordisk is offering a temporary introductory price of $199 per month for the two lowest doses of each drug for new patients, followed by a standard price cut to $349 per month from $499 per month. This complements other initiatives, including potential discounts through the upcoming TrumpRx platform and deals with telehealth providers and retailers. Eli Lilly has also announced price reductions on its weight loss drug, Zepbound, via its direct-to-consumer platform.
News Article:
Novo Nordisk Cuts Prices on Wegovy and Ozempic, Following Trump Administration Deals
[City, State] – In a move aimed at improving affordability and accessibility, Novo Nordisk announced Monday that it is reducing the direct-to-consumer prices of its blockbuster drugs Wegovy (for weight loss) and Ozempic (for diabetes). The price cuts are for cash-paying patients and follow recent agreements with the Trump administration to make GLP-1 drugs more accessible to Americans.
The Danish pharmaceutical company is lowering the standard monthly price to $349 from $499 for existing cash-paying patients. The price of the highest dose of Ozempic will remain at $499 per month.
Novo Nordisk is also introducing a limited-time offer for new patients. Starting today, new cash-paying patients can access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. This introductory offer is set to expire on March 31.
The price changes come on the heels of deals brokered by the Trump administration with Novo Nordisk and rival Eli Lilly to lower the prices of their GLP-1 drugs and increase accessibility. These agreements include potential discounts through the upcoming TrumpRx platform, set to launch in January, and expanded Medicare coverage for obesity drugs for some patients.
“Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations. “It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs.”
The Trump administration has stated that starting doses of Wegovy and Eli Lilly’s Zepbound will be $350 per month on TrumpRx, trending down to $245 per month over two years.
Eli Lilly recently announced that it would lower the price of its Zepbound, offering the lowest dose at $299 per month and additional doses up to $449 per month.
Novo Nordisk’s new offers are available through Wegovy.com, Ozempic.com, the company’s direct-to-consumer pharmacy NovoCare, and participating partners including Costco, GoodRx, WeightWatchers, Ro, LifeMD and eMed.
First Piper 